Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hem/Onc > hemostasis pharmacology and transfusion therpay > Flashcards

hemostasis pharmacology and transfusion therpay Flashcards

1
Q

major blood group systems

A

ABO
Rh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

3 pre-transfusion testing

A
  1. typing - ensures ABO/Rh compatibility
  2. antibody screen - tests for unexpected antibodies
  3. crossmatch - tests patient’s serum against prospective unit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Type testing determines the ABO and Rh phenotype of ____ blood

A

recipients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how to perform a type and screen test?

A
  1. mix recipient’s blood with type O that contains major antigens of other blood group systems
  2. observe for agglutination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

when do you only order a cross-match test?

A

when there is a high likelihood that patient will receive PRBCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what do you use during an emergency setting with not enough time to type or match blood?

A

use O-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

3 reasons why we use transfusion therapy

A
  1. replace acute blood loss
  2. oxygen delivery
  3. morbidity and mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

who do we recommend transfusion for?

A

hgb <6 g/dL - transfusion recommended except in exceptional circumstances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

assessment post-transfusion hgb lvl can be performed as early as ?

A

15 mins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

1 unit of PRBCs should increase hgb ___ in avg sized adults

A

1 g/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

prior to non-emergency transfusions, what must you obtain?

A

signed informed consent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

transfusion reactions occur when?

A
  1. during transfusion
  2. within 24 hrs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the most common sign of a transfusion reaction?

A

febrile non-hemolytic reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the top 2 causes of death from transfusion reaction

A
  1. circulatory overload
    - CHF, renal failure more at risk
  2. transfusion related acute lung injury
    - smokers, asthma more at risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

5 types of transfusion products

A
  1. whole blood
  2. packed RBC (PRBC)
  3. fresh frozen plasma (FFP)
  4. cryoprecipitate
  5. platelets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what type of transfusion product provides O2-carrying capacity and volume expansion and commonly used during settings of massive hemorrhage

A

whole blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what type of transfusion product increases the oxygen-carrying capacity in anemic pts

A

PRBC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

3 modifications of RBCs to prevent reactions

A
  1. leukocyte reduced - reduces risk of immunologically-mediated effects
  2. irradiated - reduces graft-vs-host disease (GVHD)
  3. washed - reduces complications associated with infusion of proteins in residual plasma in red cell concentrates
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what contains platelets and proteins (procoagulant and anticoagulant factors)

A

plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what 6 components are contained in fresh frozen plasma (FFP)

A
  1. coagulation factors
  2. fibrinogen
  3. antithrombin
  4. albumin
  5. protein C
  6. protein S
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

why is FFP the most commonly used plasma product?

A

can correct deficiencies of any of the circulating coagulation factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

main advantage of cryoprecipitate

A

allows vWF, factor VIII, factor XIII, and fibrinogen to be replaced using a much smaller volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

main advantage of factor concentrates

A

replaces specific factor deficiencies with minimal volume ONLY (no extra proteins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

4 indications for transfusion of PLT in critically ill pt that may be therapeutic or prophylactic

A
  1. PLT <10k - prevents hemorrhage
  2. PLT <50k
    - actively bleeding
    - scheduled for invasive procedure
    - qualitative intrinsic PLT disorder
  3. PLT <100k
    - CNS injury
    - multisystem trauma
    - neurosurgery
  4. normal PLT
    - active bleeding
    - PLT dysfunctions - congenital PLT disorder, chronic aspirin use, uremia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

each unit of transfused PLT should increase the PLT count by ?

A

5-10k

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

4 hemostasis promoting agents

A
  1. protamine sulfate
  2. vit K
  3. desmopressin
  4. thrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

neutralizes heparin and could result in severe hypotensive or anaphylactoid-like reactions (BBW)

A

protamine sulfate
reverses anticoagulant effect of heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

dosage of protamine sulfate

A

depends on dosage of heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

what is the reversal agent for warfarin (coumadin)

A

vitamin K (phytonadione)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

dosage and route of vit K depends on:

A
  1. severity of bleeding
  2. INR
  3. procedure planned
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MOA of desmopressin (DDAVP)

A

increases plasma level of vWF, factor VIII, and tPA = shortened activated partial thromboplastin time (aPTT) and bleeding time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

indication for desmopressin and what must you monitor

A

hemostasis
- restrict fluid intake
- monitor sodium levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

MOA of topical thrombin

A

converts fibrinogen to fibrin directly at site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

indication for topical thrombin

A

hemostasis whenever oozing blood and minor bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

contraindications for topical thrombin

A
  1. sensitivity to components of bovine origin
  2. massive bleeding
  3. large vessels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

3 classes of antithrombotic drugs

A
  1. antiplatelet
  2. anticoagulant
  3. fibrinolytic agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

general indication for anticoagulants

A

prevent or treat clots!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

contraindications for anticoagulants (3)

A
  1. bleeding
  2. impaired renal function
  3. allergic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

4 parenteral anticoagulants

A
  1. heparin (unfractionated)
  2. low-molecular-weight heparin (LMWH)
  3. bivalirudin (angiomax)
  4. argatroban (acova)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

MOA of unfractionated heparin

A

binds to antithrombin (III) = no activation of factor Xa and thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

no dosage adjustment is necessary for who when taking unfractionated heparin

A

renal patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

when on unfractionated heparin, you must monitor:

A

activated partial thromboplastin time (aPTT)
order daily CBC, monitor signs of bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

4 SE of unfractionated heparin

A
  1. bleeding
  2. thrombocytopenia
  3. osteoporosis
  4. elevate levels of transaminases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

7 contraindications for unfractionated heparin

A
  1. HIT
  2. hypersensitivity
  3. active bleeding
  4. hemophilia (inherited bleeding disorder in which the blood does not clot properly)
  5. significant thrombocytopenia
  6. purpura
  7. severe HTN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

what is HIT?

A

heparin-induced thrombocytopenia
induces immune antibody response resulting in PLT clearance and may also induce hypercoagulable state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

when can HIT occur?

A

any dose, schedule, and route
more common in females

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

what is the most common manifestation of HIT

A

thrombocytopenia
a platelet count drop of >50% of baseline is typical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

typical onset of HIT occurs ? after the initiation of heparin

A

5-10 d
takes 5-7 d to return to baseline following withdrawal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

what is the most common thrombi in HIT and where is it most common

A

venous
sites: leg veins, cardiac vessels, small venules of skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

5 signs of suspected HIT

A
  1. new onset of thrombocytopenia <150k
  2. drop in PLT of +50% from prior value
  3. venous/arterial thrombosis
  4. necrotic skin lesions at injection site
  5. acute systemic reactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

what is the 4Ts scoring system for assessing HIT

A

1-3 = low
4 or 5 = intermediate
6-8 = high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

how do you manage HIT

A
  1. STOP heparin
  2. start anticoagulation with a non-heparin anticoagulant
  3. long-term oral anticoagulation (warfarin) with bridging drug (lovenox)
    (do not give platelet transfusion)
53
Q

lovenox

A

LMWH

54
Q

enoxaparin

A

LMWH

55
Q

MOA of LMWH

A

enhance inhibition of factor Xa by AT III = less direct inhibition of Xa and virtually no direct inhibition of thrombin

56
Q

contraindication for LMWH

A

renal impairment/ESRD
reduced dosing with CrCl <30

57
Q

monitoring for LMWH

A

not necessary most of the time
recommended in:
- pregnancy
- CrCl <30
- morbid obesity

58
Q

SE of LMWH

A

same as heparin but less common
- bleeding
- HIT
-osteoporosis

59
Q

what is recommended over heparin?

A

LMWH
LMWH is pregnancy cat. B
heparin is pregnancy cat. C

60
Q

what are the pros and cons of LMWH over heparin?

A

advantages:
- better bioavailability and longer half-life
- dose-independent CL
- predictable anticoagulant response
- lower risk of heparin-induced thrombocytopenia
- lower risk of osteoporosis
consequences:
- can be given SQ 1-2x daily for both prophylaxis and treatment
- simplified dosing
- coagulation monitoring is unnecessary in most patients
- safer tan heparin for short/long term
- safer than heparin for extended administration

61
Q

what is often used as a bridging drug?

A

lovenox

62
Q

when should bridging should be done?

A

before and after surgery or invasive procedures in a pt already on warfarin with the following circumstances:
1. embolic stroke within past 3 months
2. previous embolic stroke or VTE during interruption of chronic anticoagulation
3. mechanical heart valve
4. A Fib with high stroke risk

63
Q

MOA of argatroban

A

direct, highly-selective thrombin inhibitor
reversibly binds to active thrombin site = inhibits fibrin formation

64
Q

Dose reduction of argatroban with who? how do you adjust dosing?

A

liver impairment
measure aPTT to adjust dose

65
Q

onset of argatroban is ____

A

immediate

66
Q

indications for argatroban

A

HIT

67
Q

what is the most severe SE of argatroban

A

bleeding

68
Q

MOA of bivalirudin

A

direct, highly-selective thrombin inhibitor
reversibly binds to the active thrombin site

69
Q

CL of bivalirudin

A

renally
must reduce dosing with renal impairment

70
Q

indications for bivalirudin

A

alternative to heparin in pt underoging percutaneous coronary intervention (PCI), esp hx of HIT

71
Q

2 oral anticoagulants

A
  1. warfarin
  2. DOACs
72
Q

what is a vitamin K antagonist

A

warfarin

73
Q

MOA of warfarin

A

inhibits vit K oxide reductase complex subunit I = inhibits factors II, VII, IX and X

74
Q

when on warfarin, you must monitor ___ for dosage adjustments

A

PT/INR
no dosage adjustments with renal impairment

75
Q

what is the pregnancy risk factor of warfarin

A

preg cat D for those with mechanical heart valve and X for all others

76
Q

indications for warfarin

A
  1. prophylaxis and tx for thromboembolic disorders (DVT/PE)
  2. embolic complications arising from afib or cardiac valve replacement
77
Q

major SE of warfarin

A

bleeding

78
Q

dietary interactions of warfarin

A
  1. alcohol - avoid!!
    - binge drinking - decreases metabolism of warfarin, increases PT/INR
    - chronic daily alc - increases metabolism, decreases PT/INR
  2. foods
    - rich in vit K - can decrease effects of warfarin
    - vit E - can increase
    - cranberry juice - can increase
    (maintain a consistent diet)
79
Q

dabigatran (pradaxa)

A

DOAC

80
Q

rivaroxaban

A

DOAC

81
Q

apixaban

A

DOAC

82
Q

edoxaban

A

DOAC

83
Q

MOA of dabigatran (pradaxa)

A

inhibits thrombin
direct thrombin inhibitor

84
Q

indications for DOACs

A
  1. stroke prevention in:
    - nonvalvular afib
    - DVT/PE
    - DVT/PE prophylaxis after hip/knee arthroplasty
85
Q

what is given to pts on dabigatran (pradaxa) to reverse anticoagulant effects for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding

A

praxbind (idarucizumab)

86
Q

MOA of rivaroxaban (xarelto)

A

inhibits factor Xa

87
Q

why are DOACs more convenient to administer than warfarin

A

given in fixed doses without routine coagulation monitoring
no monitoring required for dosage adjustment

88
Q

what is given to pts on rivaroxaban (xarelto) to reverse anticoagulant effects for emergencies

A

AndexXa

89
Q

MOA of apixaban (eliquis)

A

inhibits factor Xa

90
Q

pts on apixaban (eliquis) should not take with _____

A

grapefruit juice
avoid cyp3A4 inhibitors

91
Q

what is given to pts on apixaban (eliquis) to reverse anticoagulant effects during emergencies

A

AndexXa

92
Q

MOA of edoxaban (savaysa)

A

inhibits factor Xa

93
Q

DOACs dosing are reduced with ?

A

renal impairment

94
Q

Main SE of DOACs

A

bleeding

95
Q

MOA of aspirin

A

inhibits COX-1 production
- enzyme in biosynthesis of thromboxane A2

96
Q

what irreversibly acetylates COX enzymes

A

aspirin

97
Q

when taking clopidogrel, what should you avoid?

A

other drugs that inhibit CYP2C19
- omeprazole
- esomeprazole
can reduce effects of clopidogrel

98
Q

MOA of clopidogrel (plavix)

A
  1. inhibit ADP pathway of PLT
  2. irreversibly blocks ADP receptor (P2Y12)
    requires metabolic activation
99
Q

MOA of prasugel (effient)

A

irreversibly blocks ADP receptor (P2Y12)
requires metabolic activation

100
Q

contraindication for prasugrel (effient)

A

hx of TIA or CVA

101
Q

what irreversibly blocks ADP receptor (P2Y12) and triggers activation of GPIIb/IIIa receptor complex = reduces platelet aggregation

A

ticlopidine (ticlid)

102
Q

SE of ticlopidine

A

hematologic rxns:
- neutropenia
- agranulocytosis
- thrombotic thrombocytopenia purpura (TTP)
- aplastic anemia

103
Q

MOA of ticagrelor (brilinta)

A

reversibly and non-competitively binds to ADP P2Y12 receptor on platelets = prevents ADP-mediated activation of the GPIIb/IIIa receptor complex = reduces platelet aggregation
does NOT require metabolic activation

104
Q

MOA of cangrelor (kengreal)

A

reversibly and non-competitively binds to ADP P2Y12 receptor on platelets = prevents ADP-mediated activation of the GPIIb/IIIa receptor complex = reduces platelet aggregation

105
Q

what is the onset of cangrelor (kengreal)

A

immediate

106
Q

MOA of eptifibatide (integrilin), Abciximab (reopro)

A

GPIIb/IIa receptor inhibitor = blocks receptors = inhibiting
PLT aggregation and activation

107
Q

SE of eptifibatide (integrilin), Abciximab (reopro)

A
  1. bleeding
  2. thrombocytopenia
    - immune mediated
108
Q

major SE platelet aggregation inhibitors

A

bleeding

109
Q

what do you use to breakdown thrombi in a life-threatening setting or massive thrombi

A

fibrinolytics

110
Q

MOA of fibrinolytics

A

converts plasminogen to plasmin = degrades fibrin matrix of thrombi = makes soluble fibrin degradation products

111
Q

alteplase (tPA)

A

fibrinolytic

112
Q

streptokinase

A

fibrinolytic

113
Q

what activates plasminogen already bound to fibrin, which confines fibrinolysis to the formed thrombus = avoiding systemic activation

A

alteplase (tPA)

114
Q

what is a protein created by streptococci that combines with proactivator plasminogen = catalyzes conversion of inactive plasminogen to active plasmin

A

streptokinase

115
Q

contraindication of streptokinase

A

ischemic stroke

116
Q

why must plasma be transfused within 24h once thawed?

A

concentrations of factor V and VIII declines

117
Q

monitoring for DOAC

A

none!

118
Q

Which DOAC does not have an emergency reversal

A

edoxaban

119
Q

what inhibits COX-1 and competes with ASA at the catalytic site

A

NSAIDs

120
Q

ASA should be taken at least ____ before or ____ after NSAIDs

A

60mins
8hrs

121
Q

BBW of ticagrelor (brilinta)

A

reduced effectiveness with concomitant use of ASA above 100 mg daily

122
Q

contraindications for ticagrelor (brilinta)

A

severe liver failure
active bleeding

123
Q

which platelet aggregation inhibitor requires routine monitoring

A

ticlopidine (ticlid)

124
Q

pts on rivaroxaban (xarelto) should avoiding taking ____

A

grapefruit juice
avoid CYP3A4 inhibitors

125
Q

what DOAC should you not use if CrCl > 95 mL/min

A

edoxaban (savaysa)

126
Q

what are the 3 platelet aggregation inhibitors that can be given IV

A
  1. congrelor - kengreal
  2. eptifibatide - integrilin
  3. abciximab - reopro
127
Q

why is bridging necessary when on warfarin

A

to avoid skin necrosis

128
Q

3 non-heparin anticoagulants

A
  1. argatroban
  2. fondaparinux
  3. bivalirudin
129
Q

drug interactions with dabigatran (pradaxa)

A

ketoconazole, cyclosporin, tacrolimus

Hem/Onc (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions